Le guide de référence sur l'édition génomique.
Menu
Accueil Apprendre Actualités Demandez à l'Atlas
Explorer Technologies Maladies Traitements Essais cliniques Entreprises Scientifiques Gènes Recherche Institutions
Au-delà de la médecine Agriculture Éthique Investissement Carte du monde
Apprendre & Outils Commencer ici Glossaire A–Z Comparer les technologies Chronologie Listes & Classements Agents IA ★ Enregistré API
À propos À propos de nous Méthodologie Sources de données Politique éditoriale Contact Avertissements

🧭 Vue guidée
Nouveau en génétique ? Nous expliquons chaque terme au fil de votre navigation, en langage clair. Les mêmes pages, avec l'aide intégrée.

⚡ Point de vue d'expert
Vous connaissez déjà la biologie. Uniquement le contenu — clair et concis, sans explications supplémentaires. C'est l'affichage par défaut.

Langue de l'interface
Mode clair

Companies

Public Gene-Editing Companies

Gene-editing companies with listed shares, as held in the Atlas.

Comment cette liste est construite

Companies in the Atlas that have shares traded on a public exchange. The Atlas does not carry share prices or market capitalisations — those change constantly, and a stale figure is worse than none.

#EntréeCatégorie Statut
1 CRISPR Therapeutics Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR… CRISPR-Cas9 platform Approved
2 Intellia Therapeutics Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human… In vivo CRISPR platform Phase III
3 Beam Therapeutics Founded by David Liu and colleagues to commercialise base editing — precision changes to… Base editing platform Phase III
4 Editas Medicine One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes… In vivo editing Preclinical
5 Prime Medicine Founded to commercialise prime editing, and the company behind the first published… Prime editing platform Phase I/II
6 Verve Therapeutics Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025… In vivo base editing Phase II
7 Caribou Biosciences Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing… Cell therapy Phase I
8 Sana Biotechnology Engineering transplanted cells to be invisible to the immune system, so they can be given… Cell engineering Phase I
9 Scribe Therapeutics Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the… Engineered editors Preclinical
10 Mammoth Biosciences Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit… Miniature editors and diagnostics Preclinical
11 Arbor Biotechnologies Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at… Novel editors Phase I
12 Vertex Pharmaceuticals The established biotechnology company that partnered on, and commercialises, the first… Large biotechnology Approved
13 bluebird bio A pioneer of lentiviral gene addition with several approved therapies — and a cautionary… Gene addition Approved
14 Tessera Therapeutics Developing 'gene writing' — mobile genetic elements repurposed to insert whole sequences… Gene writing Preclinical
15 Tune Therapeutics Turning genes up and down without changing sequence — epigenetic editing taken into early… Epigenetic editing Phase I
16 Sangamo Therapeutics The company that took gene editing into humans first, years before CRISPR existed as a… Zinc finger platform Phase III
17 Eli Lilly and Company A major pharmaceutical company that entered gene editing by acquisition, buying Verve… Large pharmaceutical Phase II
Ce que cette liste ne vous dit pasEducational information only, not investment advice, and not a complete list of listed gene-editing companies. Nothing here is a recommendation regarding any security.
Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026